antibody

RAT ANTI HUMAN HER2/neu

MBS212317

0.2 mg

380 USD

monoclonal

rat

nonconjugated

ICR52

immunohistochemistry, immunohistochemistry - frozen section

Antibody

RAT ANTI HUMAN HER2/neu

HER2/neu

receptor tyrosine-protein kinase erbB-2 isoform b; Receptor tyrosine-protein kinase erbB-2; receptor tyrosine-protein kinase erbB-2; c-erb B2/neu protein; herstatin; human epidermal growth factor receptor 2; metastatic lymph node gene 19 protein; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; p185erbB2; proto-oncogene Neu; proto-oncogene c-ErbB-2; tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; erb-b2 receptor tyrosine kinase 2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD_antigen: CD340

HER2/neu

ERBB2; ERBB2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; HER2; MLN19; NEU; NGL; MLN 19

ERBB2_HUMAN

Monoclonal

IgG2b

ICR52

Rat

1225

This antibody recognises epitope C of human HER2/neu, otherwise known as CD340 and c-ErbB-2, a proto-oncogene expressed at the cell surface of a range of tumour cells, which is often associated with poor prognosis, and an increased risk of metastasis. HER2/neu is used in conjunction with antibodies recognising both Estrogen and Progesterone receptors, for the classification of breast cancer tumours, and to determine patient prognosis and course of treatment. Excessive HER2/neu is present in around 20% to 25% of invasive breast cancers, referred to as HER2-positive cancer, and can help determine whether drugs such as trastuzumab (Herceptin) or lapatinib (Tykerb), might be beneficial.

Purified. Purified IgG - liquid

IgG concentration 1.0 mg/ml

Store at 4 degree C or at -20 degree C if preferred. This product should be stored undiluted. Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. Shelf Life: 18 months from date of despatch.

Immunohistology Frozen

Perservative Stabilisers: 0.02% Sodium Azide. Preparation: Purified IgG prepared by ion exchange chromatography from tissue culture supernatant

Buffer Solution: Phosphate buffered saline. Target Species: Human

This antibody recognises epitope C of human HER2/neu, otherwise known as CD340 and c-ErbB-2, a proto-oncogene expressed at the cell surface of a range of tumour cells, which is often associated with poor prognosis, and an increased risk of metastasis.HER2/neu is used in conjunction with antibodies recognising both Estrogen and Progesterone receptors, for the classification of breast cancer tumours, and to determine patient prognosis and course of treatment. Excessive HER2/neu is present in around 20% to 25% of invasive breast cancers, referred to as HER2-positive cancer, and can help determine whether drugs such as trastuzumab (Herceptin) or lapatinib (Tykerb), might be beneficial.

54792098

NP_001005862.1

NM_001005862.2

P04626

97,253 Da

Adaptive Immune System Pathway (366160); Adherens Junction Pathway (83070); Adherens Junction Pathway (481); Alpha6-Beta4 Integrin Signaling Pathway (198807); Axon Guidance Pathway (105688); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Calcium Signaling Pathway (83050); Calcium Signaling Pathway (459); Central Carbon Metabolism In Cancer Pathway (1059538)

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]

HER2: a proto-oncogenic receptor tyrosine kinase of the EGFR family. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. Not activated by EGF, TGF- alpha and amphiregulin. Amplified in breast cancer. Overexpression induces constitutive activity, and the gene is amplified or overexpressed in up to 30% of breast cancers, correlating with poor survival. The antibody Herceptin is approved for treatment of metastatic breast cancer with HER2 amplification/overexpression. Somatic mutations seen in 4% of lung cancers and also in breast, gastric, ovarian cancer and glioblastoma. One SNP shows predisposition to breast and gastric cancer. Inhibitors: Herceptin, lapatinib, PKI-166, EKB-569, CI-1033. Protein type: Kinase, protein; Membrane protein, integral; Protein kinase, tyrosine (receptor); Protein kinase, TK; Oncoprotein; EC 2.7.10.1; TK group; EGFR family. Chromosomal Location of Human Ortholog: 17q12. Cellular Component: basolateral plasma membrane; perinuclear region of cytoplasm; cytoplasm; apical plasma membrane; integral to membrane; plasma membrane; endosome membrane; cytoplasmic vesicle; nucleus; receptor complex. Molecular Function: protein C-terminus binding; protein dimerization activity; identical protein binding; receptor signaling protein tyrosine kinase activity; transmembrane receptor protein tyrosine kinase activity; protein phosphatase binding; protein binding; transmembrane receptor activity; ErbB-3 class receptor binding; protein heterodimerization activity; growth factor binding; protein-tyrosine kinase activity; ATP binding. Biological Process: myelination; axon guidance; phosphoinositide 3-kinase cascade; positive regulation of cell adhesion; peptidyl-tyrosine phosphorylation; positive regulation of translation; wound healing; nerve growth factor receptor signaling pathway; protein amino acid autophosphorylation; heart development; motor axon guidance; signal transduction; protein amino acid phosphorylation; enzyme linked receptor protein signaling pathway; positive regulation of transcription from RNA polymerase I promoter; positive regulation of MAP kinase activity; cell surface receptor linked signal transduction; oligodendrocyte differentiation; neuromuscular junction development; epidermal growth factor receptor signaling pathway; negative regulation of immature T cell proliferation in the thymus; regulation of microtubule-based process; phosphoinositide-mediated signaling; fibroblast growth factor receptor signaling pathway; transcription, DNA-dependent; regulation of angiogenesis; positive regulation of cell growth; peripheral nervous system development; cell proliferation; innate immune response; positive regulation of transcription from RNA polymerase III promoter; positive regulation of protein amino acid phosphorylation; positive regulation of epithelial cell proliferation; transmembrane receptor protein tyrosine kinase signaling pathway. Disease: Gastric Cancer; Lung Cancer; Glioma Susceptibility 1

0.2 mg

380 USD